HRP20100302T1 - Sinteza inzulinotropnog peptida - Google Patents
Sinteza inzulinotropnog peptida Download PDFInfo
- Publication number
- HRP20100302T1 HRP20100302T1 HR20100302T HRP20100302T HRP20100302T1 HR P20100302 T1 HRP20100302 T1 HR P20100302T1 HR 20100302 T HR20100302 T HR 20100302T HR P20100302 T HRP20100302 T HR P20100302T HR P20100302 T1 HRP20100302 T1 HR P20100302T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- side chain
- fragment
- acid sequence
- Prior art date
Links
- 230000002473 insulinotropic effect Effects 0.000 title claims abstract 11
- 238000010647 peptide synthesis reaction Methods 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 claims abstract 27
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract 20
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract 20
- 238000000034 method Methods 0.000 claims abstract 17
- 239000012634 fragment Substances 0.000 claims abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 11
- 108010016626 Dipeptides Proteins 0.000 claims abstract 4
- 239000004475 Arginine Substances 0.000 claims abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000001413 amino acids Chemical group 0.000 claims 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 230000008878 coupling Effects 0.000 claims 6
- 238000010168 coupling process Methods 0.000 claims 6
- 238000005859 coupling reaction Methods 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 238000010511 deprotection reaction Methods 0.000 claims 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- -1 methyl alanine Chemical compound 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 238000003032 molecular docking Methods 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Postupak izrade inzulinotropnog peptida, naznačen time, da sadrži slijedeće korake od a) do f): a) pribavljanje prvog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu HX8EX10 (SEQ. ID NO. 6), gdje svaki od X8 i X10 je ostatak akiralne amino kiseline, svaki od H i E po izboru uključuje zaštitu bočnog lanca; b) pribavljanje drugog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu TFTSDVX17-18YLEG (SEQ. ID NO. 8) gdje ostatak označen simbolom X17-18 je dipeptidni ostatak pseudoprolina, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca; c) kupiranje prvog fragmenta na drugi fragment da bi se pribavio treći peptidni fragment koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVX17-18YLEG (SEQ. ID NO. 11), navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca; d) pribavljanje četvrtog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35 (SEQ. ID NO. 9) gdje X35 je ostatak akiralne amino kiseline, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca; e) kupiranje četvrtog peptidnog fragmenta na arginin da bi se pribavio peti peptidni fragment koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35 R (SEQ. ID NO. 12), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca; tef) kupiranje petog fragmenta na treći fragment da bi se pribavio inzulinotropni peptid koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVX17-18YLEGQAAKEFIAWLVKX35 R (SEQ. ID NO. 13), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca. Patent sadrži još 18 patentnih zahtjeva
Claims (19)
1. Postupak izrade inzulinotropnog peptida, naznačen time, da sadrži slijedeće korake od a) do f):
a) pribavljanje prvog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu HX8EX10 (SEQ. ID NO. 6), gdje svaki od X8 i X10 je ostatak akiralne amino kiseline, svaki od H i E po izboru uključuje zaštitu bočnog lanca;
b) pribavljanje drugog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu TFTSDVX17-18YLEG (SEQ. ID NO. 8) gdje ostatak označen simbolom X17-18 je dipeptidni ostatak pseudoprolina, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
c) kupiranje prvog fragmenta na drugi fragment da bi se pribavio treći peptidni fragment koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVX17-18YLEG (SEQ. ID NO. 11), navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
d) pribavljanje četvrtog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35(SEQ. ID NO. 9) gdje X35 je ostatak akiralne amino kiseline, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
e) kupiranje četvrtog peptidnog fragmenta na arginin da bi se pribavio peti peptidni fragment koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35 R (SEQ. ID NO. 12), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca; te
f) kupiranje petog fragmenta na treći fragment da bi se pribavio inzulinotropni peptid koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVX17-18YLEGQAAKEFIAWLVKX35 R (SEQ. ID NO. 13), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca.
2. Postupak u skladu sa zahtjevom 1, naznačen time, da sadrži daljnji korak:
g) uklanjanje zaštitnih skupina s bočnog lanca da bi se pribavio inzulinotropni peptid koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVSSYLEGQAAKEFIAWLVKX35 R (SEQ. ID NO. 5) i dijelove koji ju nadopunjuju, gdje svaki od simbola X u položajima 8, 10 i 35 neovisno označava akiralni, po izboru sterički ometan amino kiselinski ostatak.
3. Postupak izrade inzulinotropnog peptida u skladu sa zahtjevom 1, naznačen time, da sadrži korake:
a) pribavljanje prvog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu HX8EX10 (SEQ. ID NO. 6), gdje svaki od X8 je amino kiselinski ostatak odgovarajući za Aib te X10 je amino kiselininski ostatak odgovarajući za glicin, te svaki od H i E po izboru uključuje zaštitu bočnog lanca;
b) pribavljanje drugog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu TFTSDVX17-18YLEG (SEQ. ID NO. 8) gdje ostatak označen simbolom X17-18 je dipeptidni ostatak pseudoprolina, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
c) kupiranje prvog fragmenta na drugi fragment da bi se pribavio treći peptidni fragment koji uključuje amino kiselinsku sekvencu HX8EX10TFTSDVX17-18YLEG (SEQ. ID NO. 11), navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
d) pribavljanje četvrtog peptidnog fragmenta koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35(SEQ. ID NO. 9) gdje X35 je amino kiselinski ostatak odgovarajući za Aib, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
e) kupiranje četvrtog peptidnog fragmenta na arginin da bi se pribavio peti peptidni fragment koji uključuje amino kiselinsku sekvencu QAAKEFIAWLVKX35 R (SEQ. ID NO. 12), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca; te
f) kupiranje petog fragmenta na treći fragment i nakon toga uklanjanje zaštitnih skupina s bočnog lanca da bi se pribavio inzulinotropni peptid formule HX8EX10TFTSDVSSYLEGQAAKEFIAWLVKX35 R (SEQ. ID NO. 5) i dijelovi koji ga nadopunjuju, gdje X8 i X35 su amino kiselinski ostaci odgovarajući za Aib i X10 je amino kiselinski ostatak odgovarajući za glicin.
4. Postupak u skladu sa zahtjevom 1 ili 3, naznačen time, da X8 je amino kiselinski ostatak odgovarajući za metil alanin.
5. Postupak u skladu sa zahtjevom 1 ili 3, naznačen time, da X10 je amino kiselinski ostatak odgovarajući za glicin.
6. Peptidni fragment, naznačen time, da ima amino kiselinsku sekvencu HX8EX10 (SEQ. ID NO. 6), gdje svaki od X8 i X10 je ostatak akiralne amino kiseline, svaki od H, E, X8 i X10 po izboru uključuje zaštitu bočnog lanca.
7. Peptidni fragment u skladu sa zahtjevom 6, naznačen time, da X8 je amino kiselinski ostatak odgovarajući za Aib te X10 je amino kiselinski ostatak odgovarajući za glicin.
8. Postupak u skladu sa zahtjevom 1, naznačen time, da inzulinotropni peptid uključuje amino kiselinsku sekvencu (SEQ. ID NO. 5) HX8EX10TFTSDVSSYLEGQAAKEFIAWLVKX35 R i dijelove koji ju nadopunjuju, gdje svaki od simbola X u položajima 8, 10 i 35 neovisno označava akiralni, po izboru sterički ometan amino kiselinski ostatak; te gdje jedan ili više amino kiselinskih ostataka po izboru uključuje zaštitu bočnog lanca.
9. Postupak u skladu sa zahtjevom 8, naznačen time, da najmanje jedan od X8 i X35 je ostatak od Aib.
10. Postupak u skladu sa zahtjevom 8, naznačen time, da X10 je ostatak od glicina.
11. Postupak u skladu sa zahtjevom 1, naznačen time, da X17-18 ima formulu
[image]
gdje Φ predstavlja ostatak bilo koje amino kiseline koja po izboru uključuje zaštitu bočnog lanca te svaki od R1 i R2 neovisno je prikladni dvovalentno vezujući udio.
12. Postupak u skladu sa zahtjevom 11, naznačen time, da Φ predstavlja ostatak od Ser koji po izboru uključuje zaštitu bočnog lanca.
13. Postupak u skladu sa zahtjevom 11, naznačen time, da R2 je -CH2-.
14. Postupak u skladu sa zahtjevom 11, naznačen time, da R1 je
[image]
gdje svaki od R3 i R4 neovisno je monovalentni udio izabran između H ili nižeg alkil; ili R3 i R4 također mogu biti ko-članovi strukture prstena.
15. Postupak u skladu sa zahtjevom 14, naznačen time, da svaki od R3 i R4 je metil.
16. Peptid ili dio koji ga nadopunjuje, naznačen time, da uključuje amino kiselinsku sekvencu TFTSDVX17-18YLEG (SEQ. ID NO. 8) gdje ostatak označen simbolom X17-18 je dipeptidni ostatak pseudoprolina; navedeni amino kiselinski ostaci po izboru uključuju zaštitu bočnog lanca.
17. Postupak u skladu sa zahtjevom 1, naznačen time, da X35je amino kiselinski ostatak od metilalanina.
18. Postupak u skladu sa zahtjevima 1 do 2, naznačen time, da inzulinotropni peptid ima amino kiselinsku sekvencu (SEQ. ID NO. 4) HAibEGTFTSDVSSYLEGQAAKEFIAWLVKAibR i dijelove koji ju nadopunjuju.
19. Postupak u skladu sa zahtjevom 18, naznačen time, da inzulinotropni peptid ima amino kiselinsku sekvencu (SEQ. ID NO. 4) HAibEGTFTSDVSSYLEGQAAKEFIAWLVKAibR i dijelove koji ju nadopunjuju, koja je amidirana na C-kraju.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81591906P | 2006-06-23 | 2006-06-23 | |
| PCT/EP2007/056052 WO2007147816A1 (en) | 2006-06-23 | 2007-06-19 | Insulinotropic peptide synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100302T1 true HRP20100302T1 (hr) | 2010-06-30 |
Family
ID=38596729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100302T HRP20100302T1 (hr) | 2006-06-23 | 2010-05-27 | Sinteza inzulinotropnog peptida |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20080004429A1 (hr) |
| EP (1) | EP2035451B1 (hr) |
| JP (1) | JP4537495B2 (hr) |
| KR (1) | KR101087859B1 (hr) |
| CN (1) | CN101563364B (hr) |
| AR (1) | AR061604A1 (hr) |
| AT (1) | ATE466881T1 (hr) |
| AU (1) | AU2007263043B2 (hr) |
| BR (1) | BRPI0713575A2 (hr) |
| CA (1) | CA2654610C (hr) |
| CL (1) | CL2007001835A1 (hr) |
| CR (1) | CR10463A (hr) |
| CY (1) | CY1110186T1 (hr) |
| DE (1) | DE602007006310D1 (hr) |
| DK (1) | DK2035451T3 (hr) |
| EC (1) | ECSP088999A (hr) |
| ES (1) | ES2341588T3 (hr) |
| HR (1) | HRP20100302T1 (hr) |
| IL (1) | IL195421A0 (hr) |
| MA (1) | MA30530B1 (hr) |
| MX (1) | MX2008015935A (hr) |
| MY (1) | MY144608A (hr) |
| NO (1) | NO20084863L (hr) |
| NZ (1) | NZ573093A (hr) |
| PL (1) | PL2035451T3 (hr) |
| PT (1) | PT2035451E (hr) |
| RS (1) | RS51281B (hr) |
| RU (1) | RU2448978C2 (hr) |
| SI (1) | SI2035451T1 (hr) |
| TW (1) | TWI331155B (hr) |
| UA (1) | UA96602C2 (hr) |
| WO (1) | WO2007147816A1 (hr) |
| ZA (1) | ZA200810072B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2205624B1 (en) | 2007-10-27 | 2016-09-07 | Corden Pharma Colorado, Inc. | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| KR20100102652A (ko) * | 2007-12-11 | 2010-09-24 | 에프. 호프만-라 로슈 아게 | 고체- 및 용액-상 조합 기법을 사용한 인슐린친화성 펩타이드 합성 |
| US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
| SG175411A1 (en) * | 2009-05-01 | 2011-12-29 | Hoffmann La Roche | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| US20110313131A1 (en) * | 2010-06-21 | 2011-12-22 | Christelle Carl | Reversed phase hplc purification of a glp-1 analogue |
| US20120157382A1 (en) | 2010-12-21 | 2012-06-21 | Siegfried Krimmer | Pharmaceutical glp-1 compositions having an improved release profile |
| WO2013086514A1 (en) * | 2011-12-08 | 2013-06-13 | Pentair Water Pool And Spa, Inc. | Aquaculture pump system and method |
| WO2013098191A1 (en) * | 2011-12-29 | 2013-07-04 | Novo Nordisk A/S | Dipeptide comprising a non-proteogenic amino acid |
| WO2014077801A1 (en) | 2012-11-13 | 2014-05-22 | Ipsen Pharma S.A.S. | Purification process for preparing highly pure taspoglutide |
| WO2014077802A1 (en) | 2012-11-13 | 2014-05-22 | Ipsen Pharma S.A.S. | Purification method of a glp-1 analogue |
| GR20140100479A (el) * | 2014-09-23 | 2016-05-05 | Novetide, Ltd., | Συνθεση λιραγλουτιδης |
| US10858414B2 (en) | 2018-03-09 | 2020-12-08 | Enzypep B.V. | Chemo-enzymatic synthesis of semaglutide, liraglutide and GLP-1 |
| KR20200130712A (ko) | 2018-03-09 | 2020-11-19 | 엔지펩 비.브이. | 리라글루티드, 세마글루티드 및 glp-1의 화학-효소적 합성 |
| EP3864032B1 (en) * | 2018-10-09 | 2022-11-30 | Fresenius Kabi iPSUM S.r.l. | Process for the manufacture of glp-1 analogues |
| TWI738260B (zh) | 2019-03-25 | 2021-09-01 | 台灣神隆股份有限公司 | 純化利拉魯肽之方法 |
| WO2020254479A1 (en) * | 2019-06-18 | 2020-12-24 | Fresenius Kabi Ipsum S.R.L. | Process for the manufacture of glucagon |
| EP3753946A1 (en) | 2019-06-18 | 2020-12-23 | Fresenius Kabi iPSUM S.r.l. | Improved process for the preparation of high purity glucagon |
| US20230406900A1 (en) * | 2022-06-01 | 2023-12-21 | Scinopharm Taiwan, Ltd. | Process for preparing glucagon-like peptide-1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281335B1 (en) * | 1993-10-08 | 2001-08-28 | Coulter Corporation | Hybridoma and anti-KC-4 humanized monoclonal antibody |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| WO1996032126A1 (en) * | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6903186B1 (en) * | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
| US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| EP1701970A2 (en) * | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Methods for recovering cleaved peptide from a support |
-
2007
- 2007-06-19 SI SI200730229T patent/SI2035451T1/sl unknown
- 2007-06-19 BR BRPI0713575-0A patent/BRPI0713575A2/pt not_active IP Right Cessation
- 2007-06-19 AT AT07765481T patent/ATE466881T1/de active
- 2007-06-19 RS RSP-2010/0267A patent/RS51281B/sr unknown
- 2007-06-19 CN CN200780023265.1A patent/CN101563364B/zh not_active Expired - Fee Related
- 2007-06-19 JP JP2009515856A patent/JP4537495B2/ja not_active Expired - Fee Related
- 2007-06-19 PL PL07765481T patent/PL2035451T3/pl unknown
- 2007-06-19 EP EP07765481A patent/EP2035451B1/en active Active
- 2007-06-19 KR KR1020087031096A patent/KR101087859B1/ko not_active IP Right Cessation
- 2007-06-19 AU AU2007263043A patent/AU2007263043B2/en not_active Ceased
- 2007-06-19 UA UAA200900414A patent/UA96602C2/ru unknown
- 2007-06-19 DE DE602007006310T patent/DE602007006310D1/de active Active
- 2007-06-19 PT PT07765481T patent/PT2035451E/pt unknown
- 2007-06-19 DK DK07765481.2T patent/DK2035451T3/da active
- 2007-06-19 MY MYPI20085211A patent/MY144608A/en unknown
- 2007-06-19 WO PCT/EP2007/056052 patent/WO2007147816A1/en active Application Filing
- 2007-06-19 CA CA2654610A patent/CA2654610C/en not_active Expired - Fee Related
- 2007-06-19 RU RU2009101969/04A patent/RU2448978C2/ru not_active IP Right Cessation
- 2007-06-19 NZ NZ573093A patent/NZ573093A/en not_active IP Right Cessation
- 2007-06-19 ES ES07765481T patent/ES2341588T3/es active Active
- 2007-06-19 MX MX2008015935A patent/MX2008015935A/es active IP Right Grant
- 2007-06-21 US US11/821,017 patent/US20080004429A1/en not_active Abandoned
- 2007-06-21 AR ARP070102735A patent/AR061604A1/es not_active Application Discontinuation
- 2007-06-22 CL CL200701835A patent/CL2007001835A1/es unknown
- 2007-06-22 TW TW096122579A patent/TWI331155B/zh not_active IP Right Cessation
-
2008
- 2008-11-19 NO NO20084863A patent/NO20084863L/no not_active Application Discontinuation
- 2008-11-20 IL IL195421A patent/IL195421A0/en unknown
- 2008-11-26 ZA ZA200810072A patent/ZA200810072B/xx unknown
- 2008-11-26 CR CR10463A patent/CR10463A/es not_active Application Discontinuation
- 2008-12-22 EC EC2008008999A patent/ECSP088999A/es unknown
- 2008-12-25 MA MA31510A patent/MA30530B1/fr unknown
-
2010
- 2010-05-27 HR HR20100302T patent/HRP20100302T1/hr unknown
- 2010-06-11 CY CY20101100519T patent/CY1110186T1/el unknown
-
2011
- 2011-05-11 US US13/105,435 patent/US20110213082A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100302T1 (hr) | Sinteza inzulinotropnog peptida | |
| Bycroft et al. | A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides | |
| WO2016140232A1 (ja) | ペプチド合成方法 | |
| KR101904808B1 (ko) | 데가렐릭스 및 이의 중간 화합물의 제조 방법 | |
| JPH02174797A (ja) | ペプチド誘導体およびその用途 | |
| CN109195618A (zh) | 用于合成α4β7肽拮抗剂的方法 | |
| RU2008135440A (ru) | Водорастворимые аналоги ссс-1065 и их конъюгаты | |
| RU2010128247A (ru) | Синтез инсулинотропных пептидов с помощью комбинированных твердофазных и растворных методик | |
| RU2010107283A (ru) | Способ получения пептида | |
| US8377891B2 (en) | Process for synthesis of cyclic octapeptide | |
| JP2018505152A5 (hr) | ||
| ATE414707T1 (de) | Verfahren zur herstellung von 4-amino-4'-demethyl-4-desoxypodophylotoxin | |
| DE60144561D1 (de) | N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide | |
| GB1521919A (en) | Process for the manufacture of human insulin | |
| Martínez et al. | Total syntheses of bacillamide C and neobacillamide A; revision of their absolute configurations | |
| Yiotakis et al. | Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase | |
| Mizuno et al. | A synthesis of a glycopeptide analogue of eel calcitonin | |
| EA201100802A1 (ru) | Синтез пептидов с использованием энзиматической активации и конденсации | |
| Itoh et al. | Control of the cytotoxicity of dansylated polytheonamide mimic, an artificial peptide ion channel, by modification of the N-terminal structure | |
| ATE419230T1 (de) | Verfahren zur herstellung von 2,6-dihalo-para- trifluoromethylanilin | |
| US20040225108A1 (en) | Novel process for production of the somatostatin analog, octreotide | |
| KR20170014624A (ko) | Tdm-621의 제조방법 | |
| Rodrigues et al. | Synthesis and conformational investigation of tetrapeptide analogues of the fragment B23-B26 of insulin | |
| GB0318205D0 (en) | Synthetic method | |
| ATE407137T1 (de) | Verfahren zur herstellung tertirer phosphine |